NCT07581028已完成1 期
An Open-Label, Randomized, Fasting, Single-Dose, Two-Sequence, Two-Period Crossover Study to Evaluate the Bioequivalence of "AJU-C715" and "C715R" in Healthy Adult Volunteers
适应症
干预措施
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 61
- 试验地点
- 1
研究概览
简要总结
To Evaluate the Safety and Pharmacokinetics of "AJU-C715" and "C715R" in Healthy Adults.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 19 Years 至 59 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Healthy adults aged 19 to less than 60 years at the time of screening
- •Weight ≥ 50 kg for men or ≥ 45 kg for women, with a calculated body mass index(BMI) of 18 to 30 kg/m² at the time of screening.
- •Those who have no congenital chronic disease or chronic disease requiring treatment and who have no pathological symptoms or findings.
- •Those who are eligible for the clinical trial based on laboratory test results(hematology, blood chemistry, serum, and urine tests) and 12-lead ECG findings during screening.
- •Those who voluntarily decide to participate and agree to comply with the cautions after hearing and fully understanding the detailed description of this clinical trial.
- •Those who agree to use highly effective methods of contraception(excluding hormonal methods) to prevent pregnancy, either for themselves or their spouse/partner, from the first administration of the investigational medicinal product until one week after the last administration, and who agree not to donate sperm or eggs during this period.
排除标准
- •Those who take barbiturate and related (causing induction or inhibition of metabolism) drug within 1 month or the first administration of clinical trial drug within 10 days.
- •Those who received investigational product or bioequivalence test drug within 6 months before the first administration of clinical trial drug.
- •Those who donated whole blood within 8 weeks, received apheresis within 2 weeks, blood transfusion within 1 month or can't refrain from donating blood from the time of written consent until the end of the study.
- •4. Those who has a history of gastrointestinal disease or surgery which may affect the absorption of the drug.
- •5. Those who exceeding an alcohol consumption criteria Alcohol: Men - 21 glass/week, Women - 14 glass/week (1 glass: Soju 50 mL, Beer 250mL or liquor: 30mL), Smoke: 20 cigarettes/day.
- •6. Those who has under
- •Those who are hypersensitive to component of the Investigational product and have the medical history
- •Those with active liver disease or persistent elevation of aminotransferase levels of unknown
- •Those taking cyclosporin
- •Those with Myopathy
- •Those with severe Renal Impairment due to Renal Failure
- •Those who has Genetic problems such as galactose intolerance, Lapp lactose deficiency or glucose-galactose malabsorption
- •Those who has a history of mental illness.
- •Those who are deemed unfit by the investigators to participate in the clinical trial for other reasons.
- •9. Women who are pregnant or who may be pregnant and breastfeed.
研究组 & 干预措施
Sequence A
Experimental
Period 1: Reference Drug, Single dose/ Period 2: Test Drug, Single dose
干预措施: Reference Drug (Drug)
Sequence A
Experimental
Period 1: Reference Drug, Single dose/ Period 2: Test Drug, Single dose
干预措施: Test Drug (Drug)
Sequence B
Experimental
Period 1: Test Drug, Single dose/ Period 2: Reference Drug, Single dose
干预措施: Test Drug (Drug)
Sequence B
Experimental
Period 1: Test Drug, Single dose/ Period 2: Reference Drug, Single dose
干预措施: Reference Drug (Drug)
研究者
研究点 (1)
Loading locations...
相似试验
招募中
1 期
Bioequivalence Study for the Safety and the Pharmacokinetics of DWJ1622, DWC202313, and DWC202314 in Healthy Volunteers Under Fasting ConditionsNCT07260851Daewoong Pharmaceutical Co. LTD.40
已完成
1 期
A Study to Investigate the Pharmacokinetics of Different Formulations and Safety of AZD5004 in Healthy Participants Aged 18 to 55 YearsNCT07455825AstraZeneca65
尚未招募
1 期
A Study to Evaluate the Safety and Pharmacokinetics of AD-118 and AD-1181 in Healthy Adult SubjectsChronic Heart FailureNCT07476157Addpharma Inc.70
已完成
1 期
Bioequivalence (BE) Study Between YHP2511 and YHP2511A in Healthy VolunteersNCT07470125Yuhan Corporation61
招募中
1 期
A Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of RO7823653 in Participants With Diabetic Macular Edema (DME)NCT07425522Genentech, Inc.93